About 20,000 Austrians die of cancer every year. This is where Aladár Szalay offers hope. He is internationally recognized for his research into the diagnosis and therapy of human cancers using living microorganisms such as bacteria and viruses. In 2001 he founded the Genelux Corporation, and in 2014 the StemImmune therapy center.
To date, Aladar Szalay continues his basic academic research at the Rudolf Virchow Center for Experimental Biomedicine, School of Medicine and the Institute of Biochemistry at the University of Würzburg. Here he leads a research program on whole-body imaging and oncolytic virotherapy. Szalay is a full professor in the Department of Radiation Oncology at the Rebecca and John Moores Comprehensive Cancer Center at the University of California, San Diego.
A native of Hungary, he studied biochemistry at the University of Halle, Germany, published 250 scientific papers and contributed more than 170 patent applications. Among other honors, he is a recipient of the Alexander von Humboldt Award.